Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors-Reference-Cited by-同舟云学术

Phase I and pharmacokinetic study of the vascular‐disrupting agent CKD‐516 (NOV120401) in patients with refractory solid tumors

Published:2020-03-12 Issue:2 Volume:8 Page:
ISSN:2052-1707
Container-title:Pharmacology Research & Perspectives
language:en
Short-container-title:Pharmacol Res Perspect

Author:

Kim Hark Kyun¹^ORCID,Kang Jeong Won¹,Park Young‐Whan²,Kim Jung Young²,Kim Minchae²,Kim Soo Jin³,Kim Se‐mi³,Ho Ryu Keun³,Yoon Seonghae⁴,Kim Yun⁵^ORCID,Cho Joo‐Youn⁵,Lee Keun Seok¹,Yun Tak¹,Kim Kiwon¹,Kwak Mi Hyang¹,Kim Tae‐Sung¹,Chung Jinsoo¹,Park Joong‐Won¹

Affiliation:

1. National Cancer Center Hospital Goyang‐si Gyeonggi‐do Republic of Korea

2. National Oncoventure National Cancer Center Goyang‐si Gyeonggi‐do Republic of Korea

3. CKD Research Center Yongin‐si Gyeonggi‐do Republic of Korea

4. Clinical Trials Center Seoul National University Bundang Hospital Bundang‐gu Seongnam‐si Republic of Korea

5. Department of Clinical Pharmacology and Therapeutics Seoul National University College of Medicine Seoul Republic of Korea

Funder

Ministry of Health and Welfare

Korea Health Industry Development Institute

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/prp2.568

Reference14 articles.

1. Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments

2. New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies

3. Combretastatins: In vitro structure-activity relationship, mode of action and current clinical status

4. Phase I Safety, Pharmacokinetic and Pharmacodynamic Evaluation of the Vascular Disrupting Agent Ombrabulin (AVE8062) in Patients with Advanced Solid Tumors

5. A phase I pharmacokinetic study of the vascular disrupting agent ombrabulin (AVE8062) and docetaxel in advanced solid tumours

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Destruction of tumor vasculature by vascular disrupting agents in overcoming the limitation of EPR effect;Advanced Drug Delivery Reviews;2022-04

2. A phase 1 dose-escalation and dose-expansion study to assess the safety and efficacy of CKD-516, a novel vascular disrupting agent, in combination with Irinotecan in patients with previously treated metastatic colorectal cancer;Investigational New Drugs;2021-04-07

3. Vascular disrupting agents in cancer therapy;European Journal of Pharmacology;2021-01

4. Virulence-attenuated Salmonella engineered to secrete immunomodulators reduce tumour growth and increase survival in an autochthonous mouse model of breast cancer;Journal of Drug Targeting;2020-12-21